At the end of its fiscal year 2023’s third quarter, SERA PROGNOSTICS ($NASDAQ:SERA) reported a total revenue of USD 0.0 million, which was a 55.6% decrease from the prior year. The company’s net income for the quarter was USD -7.2 million, an improvement from the -10.7 million seen in the same period of the previous year.
GoodWhale recently conducted an analysis of SERA PROGNOSTICS‘ wellbeing and the results show that the company is strong in terms of assets and growth, but weak in dividend and profitability. According to the Star Chart, SERA PROGNOSTICS has an intermediate health score of 4/10 with regard to its cashflows and debt, meaning it might be able to sustain future operations in times of crisis. Consequently, SERA PROGNOSTICS has been classified as a ‘cheetah’ type of company, which is characterized by high revenue or earnings growth but is considered less stable due to lower profitability. Given these characteristics, this type of company may be attractive to long-term investors looking for high returns and not so worried about short-term fluctuations in the market. Furthermore, those seeking to diversify their portfolios with growth stocks may also find such companies appealing. Ultimately, investors that take a longer-term view and are comfortable with a higher degree of risk should consider SERA PROGNOSTICS as an opportunity. More…
Star Chart Analysis
About the Company
Ownership (Institutional/ Fund Holdings)
Below shows the total revenue, net income and net margin for Sera Prognostics. More…
Income Statement Reports (Yearly/ Quarterly/ LTM)
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Sera Prognostics. More…
Cash Flow Statement (Yearly/ Quarterly/ LTM)
Cash Flow Supplement
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Sera Prognostics. More…
Balance Sheet (Yearly/ Quarterly)
Balance Sheet Supplement
||Book Value Per Share
Key Ratios Snapshot
Some of the financial key ratios for Sera Prognostics are shown below. More…
Income Statement Ratios
Balance Sheet Ratios
Cash Flow Ratios
Other Supplementary Items
|3Y Rev Growth
||3Y Operating Profit Growth
Some of its competitors include Aspira Women’s Health Inc, PT Prodia Widyahusada Tbk, and Vijaya Diagnostic Centre Ltd.
– Aspira Womens Health Inc ($NASDAQ:AWH)
Aspira Women’s Health Inc is a publicly traded company with a market capitalization of $45.68 million as of 2022. The company has a return on equity of -125.83%. Aspira Women’s Health Inc is engaged in the business of providing healthcare services to women. The company operates a network of women’s health clinics across the United States. Aspira Women’s Health Inc is headquartered in Boston, Massachusetts.
– PT Prodia Widyahusada Tbk ($IDX:PRDA)
PT Prodia Widyahusada Tbk is a leading Indonesian provider of clinical laboratory services. The company offers a wide range of services including general laboratory tests, specialized tests, and medical consultation. PT Prodia Widyahusada Tbk has a market cap of 5.25T as of 2022, a Return on Equity of 17.34%. PT Prodia Widyahusada Tbk is well-positioned to continue its growth trajectory in the years ahead, supported by its strong brand recognition, extensive network of laboratories, and commitment to providing quality services.
– Vijaya Diagnostic Centre Ltd ($BSE:543350)
Vijaya Diagnostic Centre Ltd is an Indian company that provides diagnostic services. It has a market cap of 46.93B as of 2022 and a return on equity of 19.07%. The company was founded in 1977 and is headquartered in Hyderabad, India.
SERA PROGNOSTICS reported a significant decrease in total revenue for the third quarter of fiscal year 2023, down 55.6% year over year. Despite this, net income improved from -10.7 million to -7.2 million during the same period. Despite the decrease in revenue, investors were encouraged by the improved profitability, driving the stock price up on the same day. In light of these findings, investors may be interested in studying SERA PROGNOSTICS further to determine whether long-term growth prospects exist.